Sometimes somebody, somebody else, just gets it so right you have to sit up and say, "That's it, that's dead on, that's what I am going to do." Usually for me it is

Jeff Berkowitz

, my able and trusted partner.

Sometimes it is

Byron Wien

, who has guided me through incredibly difficult times always with an eye toward making the biggest gains with the least risk. (Wien is a strategist at

Morgan Stanley Dean Witter

.) Sometimes it is my wife, the

Trading Goddess

, who worked with me for seven years running my trading desk.

This time it is

Helene Meisler

. Her

piece about the oversold

Nasdaq

and the carnage in the B2Bs on these pages is the best piece out there right now that tells me what to do. After I finished reading it I looked at my trading sheets and I said "I don't own enough Nasdaq. I gotta get longer Nasdaq. I hope I have a chance. Maybe I am going to miss a big rally off the oversold."

I am sending this piece to all my compadres at the office for them to study this weekend. I am going to do my own charting of the

Red Hots (now retitled

TheStreet.com New Tech 30

) to make sense of it. And then I am going to have to do some buying for a vicious rally off the lows that might be coming -- if my braintrust agrees with me.

A word on that by the way. We work as a team at

Cramer Berkowitz

. (That is the name of the firm, not Cramer Co.) It is entirely possible that Jeff or

Matt "I Still Believe" Jacobs

or

Todd-o Harrison

, our head trader, disagrees with me. I usually try to give you a distillation of all of our views.

But as I have just read this piece this Saturday morning, I don't have all of the inputs I need -- however Helene has made me "feel" more bullish than I did before.

Now that's an important piece!

James J. Cramer is manager of a hedge fund and co-founder of TheStreet.com. At time of publication, his fund had no positions in any stocks mentioned. Cramer's fund may be long or short certain stocks in his biotech or B2B rotisserie leagues or TheStreet.com New Tech 30 index. His fund often buys and sells securities that are the subject of his columns, both before and after the columns are published, and the positions that his fund takes may change at any time. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Cramer's writings provide insights into the dynamics of money management and are not a solicitation for transactions. While he cannot provide investment advice or recommendations, he invites you to comment on his column at

jjcletters@thestreet.com.